AMENDMENTS TO THE CLAIMS

Listing of Claims:

Claim 1 (currently amended): A method of killing melanoma cells comprising contacting said cells for an effective time with an effective amount of an <u>organic small molecule</u> inhibitor <u>of</u>

MAPK/ERK kinase (MEK) enzymes of the MAPK pathway which <u>inhibitor</u> induces apoptosis in said cells, thereby killing the cells.

Claim 2 (withdrawn)

Claim 3 (withdrawn)

Claim 4 (currently amended): The method of claim 1 wherein said inhibitor is an organic small molecule selected from the group consisting of PD98059, U0126 and PD184352.

Claim 5 (currently amended): The method of claim 4 wherein said inhibitor is PD98059, U0126 or PD184352.

Claim 6 (currently amended): The method of any of claims 1, 4 or [[-]]5, wherein said contacting is in vivo.

Claim 7 (original): The method of claim 6 wherein said killing results in measurable regression of melanoma tumor or attenuation of melanoma growth.

Claim 8 (withdrawn)

Claim 9 (currently amended): A method of inducing an antitumor response in a mammal having melanoma, comprising administering an effective amount of an <u>organic small molecule</u> inhibitor <u>of MEK enzyme of the MAPK pathway</u> to said mammal, which inhibitor <u>induces apoptosis in and is cytotoxic to melanoma cells in said mammal</u>, thereby inducing an antitumor response that comprises is (a) a partial antitumor response characterized by

- (i) at least a 50% decrease in <u>tumor size measured as</u> the sum of the products of maximal perpendicular diameters of all measurable lesions;
- (ii) <u>absence no evidence</u> of new lesions, and
- (iii) <u>lack of no progression of any preexisting lesions, or</u>

(b) a complete antitumor response characterized by the disappearance of all evidence of melanoma disease for at least one month.

Claim 10 (currently amended): The method of claim 9 wherein said antitumor response is a partial antitumor response further comprises the disappearance of all evidence of melanoma disease for at least one month.

Claim 11 (withdrawn)

Claim 12 (withdrawn)

Claim 13 (currently amended): The method of claim 9 wherein said inhibitor is an organic small molecule selected from the group consisting of PD98059, U0126 and PD184352.

Claim 14 (currently amended): The method of claim 13 wherein said inhibitor is PD98059, U0126 or PD184352.

Claim 15 (currently amended): The method of any of claims 9, 10, 13 or [[-]]14, wherein said mammal is a human.

Claim 16 (currently amended): A method of inhibiting growth or recurrent growth of a melanoma tumor in a mammal having melanoma or at risk for melanoma growth or recurrence, comprising administering an effective amount of an <u>organic small molecule</u> inhibitor <u>of MEK enzyme MAPK pathway</u> to said mammal, thereby inducing a cytotoxic response leading to apoptosis of melanoma cells in said mammal, which <u>response</u> inhibits said growth or recurrent growth of said melanoma tumor.

Claim 17 (withdrawn)

Claim 18 (withdrawn)

Claim 19 (currently amended): The method of claim 16 wherein said inhibitor is an organic small molecule selected from the group consisting of PD98059, U0126 and PD184352.

Claim 20 (currently amended): The method of claim 19 wherein said inhibitor is PD98059, U0126 of PD184352.

Claim 21 (currently amended): The method of any of claims 16, 19 or [[-]]20, wherein said mammal is a human.